Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid TumorsAditi Shastri,Eric J. Feldman, Alexander N. Starodub,Tatyana Feldman,Cristina P. Rodriguez,Zachary D. Epstein-Peterson,Don A. Stevens,Adam J. Olszewski,Auris O. Huen,Pierluigi Porcu,John C. Reneau,Stefan K. Barta,Enrica Marchi, Ahmad H. Mattour,Lauren C. Pinter-Brown,Rachelle Perea,Sean Donohue,Joyoti Dey,Sagar Agarwal,Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D. SmithBLOOD（2023）引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
